143 related articles for article (PubMed ID: 11505204)
1. FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation.
Oyama N; Akino H; Suzuki Y; Kanamaru H; Ishida H; Tanase K; Sadato N; Yonekura Y; Okada K
Nucl Med Commun; 2001 Sep; 22(9):963-9. PubMed ID: 11505204
[TBL] [Abstract][Full Text] [Related]
2. [PET/CT with (11)C-choline and (18)F-FDG in patients with elevated PSA after radical treatment of a prostate cancer].
García JR; Soler M; Blanch MA; Ramírez I; Riera E; Lozano P; Pérez X; Delgado E; Carrio I; Lomeña F
Rev Esp Med Nucl; 2009; 28(3):95-100. PubMed ID: 19558948
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. The increased accumulation of [18F]fluorodeoxyglucose in untreated prostate cancer.
Oyama N; Akino H; Suzuki Y; Kanamaru H; Sadato N; Yonekura Y; Okada K
Jpn J Clin Oncol; 1999 Dec; 29(12):623-9. PubMed ID: 10721945
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
Soga N; Onishi T; Arima K; Sugimura Y
Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
[TBL] [Abstract][Full Text] [Related]
6. [18F]Fluorodeoxyglucose positron emission tomography surveillance of hepatic metastases from prostate cancer following radiofrequency ablation: a case report.
Ludwig V; Hopper OW; Martin WH; Kikkawa R; Delbeke D
Am Surg; 2003 Jul; 69(7):593-8. PubMed ID: 12889623
[TBL] [Abstract][Full Text] [Related]
7. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse.
Oyama N; Miller TR; Dehdashti F; Siegel BA; Fischer KC; Michalski JM; Kibel AS; Andriole GL; Picus J; Welch MJ
J Nucl Med; 2003 Apr; 44(4):549-55. PubMed ID: 12679398
[TBL] [Abstract][Full Text] [Related]
8. Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients.
Fricke E; Machtens S; Hofmann M; van den Hoff J; Bergh S; Brunkhorst T; Meyer GJ; Karstens JH; Knapp WH; Boerner AR
Eur J Nucl Med Mol Imaging; 2003 Apr; 30(4):607-11. PubMed ID: 12589476
[TBL] [Abstract][Full Text] [Related]
9. Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer.
Nuñez R; Macapinlac HA; Yeung HW; Akhurst T; Cai S; Osman I; Gonen M; Riedel E; Scher HI; Larson SM
J Nucl Med; 2002 Jan; 43(1):46-55. PubMed ID: 11801702
[TBL] [Abstract][Full Text] [Related]
10. [Giant prostate carcinoma treated effectively with endocrine therapy: case report].
Masue N; Hasegawa Y
Hinyokika Kiyo; 2007 Feb; 53(2):133-5. PubMed ID: 17352166
[TBL] [Abstract][Full Text] [Related]
11. FDG PET/CT imaging in prostate adenocarcinoma presenting as isolated brain metastases of unknown origin.
Erhamamcı S; Reyhan M; Alkan O
Rev Esp Med Nucl Imagen Mol; 2015; 34(2):146-7. PubMed ID: 25052407
[No Abstract] [Full Text] [Related]
12. Clinical Relevance of Incidental Prostatic Lesions on FDG-Positron Emission Tomography/Computerized Tomography-Should Patients Receive Further Evaluation?
Reesink DJ; Fransen van de Putte EE; Vegt E; De Jong J; van Werkhoven E; Mertens LS; Bex A; van der Poel HG; van Rhijn BW; Horenblas S; Meijer RP
J Urol; 2016 Apr; 195(4 Pt 1):907-12. PubMed ID: 26598424
[TBL] [Abstract][Full Text] [Related]
13. Incidental abnormal FDG uptake in the prostate on 18-fluoro-2-deoxyglucose positron emission tomography-computed tomography scans.
Kang PM; Seo WI; Lee SS; Bae SK; Kwak HS; Min K; Kim W; Kang DI
Asian Pac J Cancer Prev; 2014; 15(20):8699-703. PubMed ID: 25374193
[TBL] [Abstract][Full Text] [Related]
14. The potential of FDG-PET/CT for detecting prostate cancer in patients with an elevated serum PSA level.
Minamimoto R; Uemura H; Sano F; Terao H; Nagashima Y; Yamanaka S; Shizukuishi K; Tateishi U; Kubota Y; Inoue T
Ann Nucl Med; 2011 Jan; 25(1):21-7. PubMed ID: 20931305
[TBL] [Abstract][Full Text] [Related]
15. Fluorodeoxyglucose positron emission tomography studies in the diagnosis and staging of clinically advanced prostate cancer.
Sung J; Espiritu JI; Segall GM; Terris MK
BJU Int; 2003 Jul; 92(1):24-7. PubMed ID: 12823377
[TBL] [Abstract][Full Text] [Related]
16. Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer.
Price DT; Coleman RE; Liao RP; Robertson CN; Polascik TJ; DeGrado TR
J Urol; 2002 Jul; 168(1):273-80. PubMed ID: 12050555
[TBL] [Abstract][Full Text] [Related]
17. Adrenocorticotropic hormone is involved in regulation of androgen synthesis in men receiving androgen deprivation therapy for localized prostate cancer.
Takizawa I; Hara N; Nishiyama T; Isahaya E; Hoshii T; Takahashi K
J Urol; 2010 Nov; 184(5):1971-6. PubMed ID: 20884032
[TBL] [Abstract][Full Text] [Related]
18. Detecting metastatic pelvic lymph nodes by 18F-2-deoxyglucose positron emission tomography in patients with prostate-specific antigen relapse after treatment for localized prostate cancer.
Chang CH; Wu HC; Tsai JJ; Shen YY; Changlai SP; Kao A
Urol Int; 2003; 70(4):311-5. PubMed ID: 12740497
[TBL] [Abstract][Full Text] [Related]
19. Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer.
Uemura H; Hasumi H; Kawahara T; Sugiura S; Miyoshi Y; Nakaigawa N; Teranishi J; Noguchi K; Ishiguro H; Kubota Y
Int J Clin Oncol; 2005 Dec; 10(6):405-10. PubMed ID: 16369744
[TBL] [Abstract][Full Text] [Related]
20. Pairwise comparison of 18F-FDG and 18F-FCH PET/CT in prostate cancer patients with rising PSA and known or suspected second malignancy.
How Kit N; Dugué AE; Sevin E; Allouache N; Lesaunier F; Joly F; Aide N
Nucl Med Commun; 2016 Apr; 37(4):348-55. PubMed ID: 26642435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]